Intriguingly, preclinical models have shown that NSCLC cell lines with EGFR mutations and EML4-ALK translocations modulate PD-L1 expression via common downstream signaling pathways such as PI3K–AKT, and MEK–ERK pathways [33]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.